Baudax Bio Inc. (BXRX)

Shareholders Approve Merger-Related Preferred Stock Conversion

October 16, 2023
Report ID: 26162
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Baudax Bio Inc.
Baudax Bio Inc.
Healthcare
Biotechnology
Ticker
BXRX
Price Target
Refer to Report
Volume
692.2K
52wk Range
$0.0137 - $3.4699
Related Research Reports
3/22/2024

Dropping Coverage
Dropping Coverage (BXRX)
10/16/2023

Shareholders Approve Merger-Related Preferred Stock Conversion
Shareholders Approve Merger-Related Preferred Stock Conversion (BXRX)
9/29/2023

Orphan Drug Designation Granted By FDA for TI-168
Orphan Drug Designation Granted By FDA for TI-168 (BXRX)
8/23/2023

A New Phase Begins For Baudax Bio With Reported 2Q 2023
A New Phase Begins For Baudax Bio With Reported 2Q 2023 (BXRX)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.